We discover small molecules which act as inhibitors of disease targets. The endpoint of our process delivers series of compounds which are ready for ADME/tox testing and are patentable. Our focus is on hard-to-drug disease targets, like Protein-Protein Interaction Inhibitors, to treat inflammation and cancer.